Genomics and Bioanalytics Group, Bioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Sci Rep. 2024 Jan 17;14(1):1534. doi: 10.1038/s41598-023-50095-3.
The majority of pharmaceuticals are derived from natural products, bioactive compounds naturally synthesized by organisms to provide evolutionary advantages. Although the rich evolutionary history of eukaryotic algal species implicates a high potential for natural product-based drug discovery, it remains largely untouched. This study investigates 2762 putative biosynthetic gene clusters (BGCs) from 212 eukaryotic algal genomes. To analyze a vast set of structurally diverse BGCs, we employed comparative analysis based on the vectorization of biosynthetic domains, referred to as biosynthetic domain architecture (BDA). By characterizing core biosynthetic machineries through BDA, we identified key BDAs of modular BGCs in diverse eukaryotes and introduced 16 candidate modular BGCs with similar BDAs to previously validated BGCs. This study provides a global characterization of eukaryotic algal BGCs, offering an alternative to laborious manual curation for BGC prioritization.
大多数药物都源自天然产物,这些生物活性化合物是生物体为了提供进化优势而自然合成的。尽管真核藻类物种丰富的进化历史暗示了基于天然产物的药物发现具有很高的潜力,但这方面的研究仍基本处于未开发状态。本研究调查了来自 212 种真核藻类基因组的 2762 个假定生物合成基因簇(BGCs)。为了分析大量结构多样的 BGCs,我们采用了基于生物合成结构域矢量化的比较分析,称为生物合成结构域架构(BDA)。通过 BDA 来表征核心生物合成机制,我们确定了不同真核生物中模块化 BGC 的关键 BDA,并引入了 16 个具有类似 BDA 的候选模块化 BGC,这些 BGC 与之前验证的 BGC 具有相似性。本研究对真核藻类 BGC 进行了全面的描述,为 BGC 的优先级排序提供了一种替代繁琐的手动策管方法。